Key Takeaway: The article discusses the top-line results of the SHINE Phase 2 clinical trial, which investigated cerebrospinal fluid (CSF) biomarkers in Alzheimer's patients. The findings were presented at the 2024 Alzheimer's Association International Conference in Philadelphia. These results are significant for advancing Alzheimer's research and potential treatments.
Price reaction · baseline $2.37 (2024-07-26 close) · hit pre-market · 3 other CGTX headline(s) in the window, move may be shared
day 0 close
-43.9%
day 1
-53.6%
day 3 · peak
-62%
Market Sentiment Analysis
POSITIVE FACTORS
Top-line results from a Phase 2 trial indicate promising outcomes.
The study focuses on CSF biomarkers, which are crucial for Alzheimer's research.
Presentation at a major conference highlights the significance of the findings.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Di Caro V, Cho E, Knezovich N, et al. Top-Line CSF Biomarker Outcomes From The Phase 2 Clinical Trial SHINE In Alzheimer’s Patients . Poster presented at 2024 Alzheimer’s Association International Conference (AAIC) ; Philadelphia, PA.
Frequently Asked Questions
What were the outcomes of the SHINE Phase 2 trial?
The SHINE Phase 2 trial reported top-line results focusing on CSF biomarkers in Alzheimer's patients.
Where was the SHINE trial presented?
The findings were presented at the 2024 Alzheimer's Association International Conference in Philadelphia.
What is the significance of CSF biomarkers?
CSF biomarkers are crucial for understanding and advancing Alzheimer's research and treatment.